Literature DB >> 16384776

Nephrogenic fibrosing dermopathy: a series in a non-Western population.

Saumya Panda1, Debabrata Bandyopadhyay, Avijit Tarafder.   

Abstract

BACKGROUND: Nephrogenic fibrosing dermopathy (NFD) is a newly proposed clinical entity resembling scleromyxedema. This is mainly found in patients with chronic renal failure who have undergone hemodialysis. Nearly all cases have been reported in the Western population.
OBJECTIVE: We sought to assess whether NFD cases occurred in a non-Western population and to ascertain the frequency, clinical characteristics, histopathology, and natural history of the condition in the event of its occurrence.
METHODS: Patients postdialysis in the nephrology department of a tertiary referral hospital in Kolkata, India, were evaluated clinically and histopathologic assessment was done on the basis of a clinical scoring to ascertain the frequency of the condition and its characteristics. This report is based on the findings of the first 3 years of an ongoing study.
RESULTS: NFD was diagnosed in 6 of 2146 patients postdialysis 0.28%). In transplant recipients undergoing dialysis, NFD was diagnosed in 2 of 43 patients (4.65%). The average number of dialyses undergone by the patients was 7.2 (range: 2-16). Of the 6 cases of NFD, 5 conformed to the diagnosis of chronic kidney disease-V. Among them, 3 were noninsulin-dependent diabetes mellitus and one each were cases of chronic glomerulonephritis and systemic lupus erythematosus. One case followed dialysis in acute tubular necrosis. All cases clinically showed circumscribed thickening, roughened texture, hardening, xerosis, and infiltrated papules, plaques, or both. One case showed rippled pigmentation, four showed varied hyperpigmentation, two demonstrated localized fibrosis, and one resembled papular mucinosis. Increased thickness of dermis, increased number of plump spindle cells, abundance of thick collagen bundles with prominent clefts, and sparse small, multinucleated histiocytes were the hallmark of microscopic findings. LIMITATIONS: The inherent nature of the study precluded the inclusion of NFD cases without any background of dialysis, which have now been reported. No statistical conclusions may be established from our small series.
CONCLUSION: To our knowledge, this is the first reported series of NFD outside North America and Europe.

Entities:  

Mesh:

Year:  2006        PMID: 16384776     DOI: 10.1016/j.jaad.2005.10.007

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

1.  Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.

Authors:  Ti-Yung Tseng; Jeng-Hwei Tseng; Bing-Shen Huang; Shen-Yen Lin; Chun-Bing Chen; Yi-Wen Fang; Gigin Lin; Ying-Chieh Lai
Journal:  Abdom Radiol (NY)       Date:  2021-03-20

Review 2.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

Review 3.  Nephrogenic systemic fibrosis: an update.

Authors:  Shawn E Cowper; Philip J Boyer
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

4.  Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.

Authors:  Zhitong Zou; Lin Ma
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

5.  Nephrogenic systemic fibrosis: time for the requiem?

Authors:  Saumya Panda
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

6.  Nephrogenic systemic fibrosis: a brief review.

Authors:  Rajesh Waikhom; Abhijit Taraphder
Journal:  Indian J Dermatol       Date:  2011-01       Impact factor: 1.494

7.  Understanding nephrogenic systemic fibrosis.

Authors:  Tushar Chopra; Kiran Kandukurti; Silvi Shah; Raheel Ahmed; Mandip Panesar
Journal:  Int J Nephrol       Date:  2012-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.